1. Home
  2. FLYW vs AGIO Comparison

FLYW vs AGIO Comparison

Compare FLYW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

N/A

Current Price

$18.19

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$34.21

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLYW
AGIO
Founded
2009
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
FLYW
AGIO
Price
$18.19
$34.21
Analyst Decision
Buy
Buy
Analyst Count
14
8
Target Price
$16.21
$38.88
AVG Volume (30 Days)
1.9M
914.1K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
N/A
EPS
0.03
N/A
Revenue
$623,025,000.00
$43,011,000.00
Revenue This Year
$19.68
$76.75
Revenue Next Year
$15.25
$170.73
P/E Ratio
$629.67
N/A
Revenue Growth
26.59
N/A
52 Week Low
$10.55
$22.24
52 Week High
$19.73
$46.00

Technical Indicators

Market Signals
Indicator
FLYW
AGIO
Relative Strength Index (RSI) 49.52 50.18
Support Level $13.34 $32.54
Resistance Level $18.94 $36.04
Average True Range (ATR) 0.59 1.17
MACD -0.06 0.15
Stochastic Oscillator 30.04 43.71

Price Performance

Historical Comparison
FLYW
AGIO

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: